Low-energy gamma emitting isotopes encapsulated for permanent implant are in routine use in the treatment of prostate cancer. New source designs require full dosimetric analysis and calibration standardization before responsible clinical application. The results of one such experimental measurement and analysis are here reported for a new design of 103palladium source, model MED3633 (North American Scientific, Inc.). By AAMP Task Group #43 recommendations, the reference material for brachytherapy dosimetry is liquid water. The dose measurements were made using standard methods employing thermoluminescent dosimeters in a water equivalent plastic phantom. Precision machined bores in the phantom located dosimeters and source(s) in a reproducible fixed geometry providing for transverse-axis and angular dose profiles over a range of distances from 0.17 to 7 cm. The data were analyzed in terms of parameters recommended by AAPM TG43. The dose-rate constant, lambda, was evaluated with reference to a 60 cobalt standard, accounting for response variation with isotope energy spectrum. The radial dose function, g(r), the anisotropy function, F(r, theta), the anisotropy factor, phi,un(r), and the point-source approximation anisotropy constant, phi(un), were derived from one- and two-dimensional dose distribution data measured in the phantom, accounting for finite dosimeter volume and with attention to interchip effects. The results are compared to TG43 and other existing data for 103Pd sources. The new source is comparable to the model 200 103Pd source design, demonstrating equivalent radial dose function, g(r). The dose surrounding a MED3633 source may be slightly more isotropic than for the model 200 source. The air-kerma strength of the MED3633 source used in this study was provided by the manufacturer and is traceable to the NIST 1999 standard. The evaluated dose-rate constant, lambda, with NIST traceable strength calibration is lower than that of the model 200 source, with that manufacturer's strength calibration.

Dosimetric measurements were performed to characterize a new 125I source that is a variant design of an existing source, designated as MED3631-A/S, and that has application in interstitial brachytherapy. The new source, designated as MED3631-A/M, has centralized radio-opaque markers. In the original MED3631-A/S source, the radio-opaque markers are separated. Thermoluminescent dosimeters were placed in phantom to measure transverse axis and angular dose profiles over a range of distances from 0.5 to 7 cm. The data were analyzed in terms of parameters recommended by AAPM Task Group No. 43. Tabular data evaluated in liquid water are provided for the dose-rate constant, lambda, radial dose function, g(r), the anisotropy function, F(r,theta), the anisotropy factor, phi(an)(r), the point-source approximation anisotropy constant, phi(an). The dose-rate constant was determined by an absolute method using a Cobalt-60 reference and by relative measurements using calibrated 125I source(s). Values of the dose-rate constant are provided for both the 1985 and 1999 NIST air-kerma strength standards. The new source is comparable to both the MED3631-A/S and the model 6702 125I source designs, demonstrating equivalent radial dose function, g(r). Differences in the value of the dose-rate constant, lambda, and the anisotropy of the dose distributions in phantom are discussed in light of the improved isotropy of the new design, the MED3631-A/M source, and the uncertainty involved in the dose measurement using a Cobalt-60 reference.

Dosimetric measurements were performed to characterize a new 125I source that is similar in design to existing sources and that has application in interstitial brachytherapy. Thermoluminescent dosimeters were placed in phantom to measure transverse-axis and angular dose profiles over a range of distances from 0.5 to 7 cm. The data were analyzed in terms of parameters recommended by AAPM Task Group #43. Tabular data evaluated in liquid water are provided for the dose-rate constant, lambda, radial dose function, g(r), the anisotropy function, F(r, theta), the anisotropy factor, phi an(r), the point-source approximation anisotropy constant, phi an, and the point-source average dose rate times the square of distance for unit air kerma strength, r2D(r). The new source is compared to the model 6702 125I source design, demonstrating similar dose-rate constant, lambda, and radial dose function, g(r). Differences in the anisotropy of the dose distributions are discussed. Finally, a comparison of the radial dose distribution is made between liquid water and tissue equivalent materials.

Permanent prostate implant using 125I or 103Pd sources is a common treatment choice in the management of early prostate cancer. As sources of new designs are developed and marketed for application in permanent prostate implants, it is of paramount importance that their dosimetric characteristics are carefully determined, in order to maintain a high accuracy of patient treatment. This report presents the results of experimental measurements of the dosimetric parameters performed for a newly available 125I seed source, the model MED3631-A/M source (IoGold), manufactured by North American Scientific, Inc. The measurements were performed in a large scanning water phantom, using a diode detector. The positioning of the source and the diode detector was achieved by a computer-controlled positioning mechanism in the scanning water phantom. The dose rate constant in water for the new 125I source was measured in comparison with an existing 125I source of similar design and verified using thermoluminescent dosimetry (TLD) measurement. The radial dose function values for the source were measured using the diode detector. The measurement technique and the results are compared with the dose distribution parameters for the 125I sources discussed in the AAPM TG43 report and elsewhere [Med. Phys. 26, 570-573 (1999)]. For the dose rate constant in water of the new source, it is recommended that a value of 0.950 cGy/U-hr be used based on the NIST 1985 air-kerma strength calibration standard, or 1.060 cGy/U-hr based on the 1999 NIST air-kerma strength standard. The measured radial dose function values for the MED3631-A/M source agree closely with those of the model 6702 source. It is therefore recommended that the radial dose function values for the model 6702 125I source, as recommended by the AAPM TG43 report, be adopted for the new source as well.

Permanent prostate implantation using 125I (iodine) or 103Pd (palladium) sources is a popular treatment option in the management of early prostate cancer. As sources of new designs are developed and marketed for application in permanent prostate implantations, their dosimetric characteristics must be carefully determined in order to maintain the accuracy of patient treatment. This report presents the results of experimental measurements and Monte Carlo calculations of the dosimetric parameters performed for a newly available 103Pd seed source. The measurements were performed in a large scanning water phantom using a diode detector. The positioning of the source and detector was achieved by a computer-controlled positioning mechanism in the scanning water phantom. The dose rate constant in water for the new 103Pd source was determined from measurements with the diode detector calibrated with 125I sources of known air-kerma strength. The radial dose function values for the source were measured using the diode detector. Monte Carlo photon transport calculations were then used to calculate the dosimetric parameters of dose rate constant, radial dose function, and anisotropy function using an accurate geometric model of the source. The measured dose rate constant of 0.693 cGy/U-hr compares well with the Monte Carlo calculated value of 0.677 cGy/U-hr. These results are further compared with data on existing 103Pd sources.